To Be Discontinued Injection Hematology
Bleomycin Sulfate Injection · 455 days since initial FDA posting
Brand: BLEOMYCIN
FDA lists Bleomycin Sulfate Injection as To Be Discontinued (Hospira, Inc., a Pfizer Company).
No availability text on this FDA row.
Bleomycin Sulfate Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Bleomycin Sulfate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)
- Package NDC
- 0409-0323-20
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jun 13, 2025
- Last Updated
- Jun 13, 2025
- Therapeutic Category
- Hematology, Oncology, Pediatric
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Bleomycin Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.